NDT Advance Access originally published online on October 24, 2008
Nephrology Dialysis Transplantation 2009 24(3):856-863; doi:10.1093/ndt/gfn593
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis
1 Center for Evidence-Based Practice, University of Pennsylvania Health System 2 Center for Clinical Epidemiology and Biostatistics 3 Renal Electrolyte and Hypertension Division 4 The Division of General Internal Medicine, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Correspondence and offprint requests to: Rajender Agarwal, 3535 Market Street, Mezzanine Level, Suite 50, Philadelphia, PA 19104, USA. Tel: +1-215-615-1720; Fax: +1-215-349-5829; E-mail: rajender.agarwal{at}uphs.upenn.edu
 |
Abstract |
|---|
Background. In the past decade, more than 200 cases of nephrogenic systemic fibrosis (NSF) have been identified, primarily among patients with advanced kidney disease. Multiple studies have suggested an association between gadolinium-based contrast agents (GBCAs) and NSF. We performed a systematic review and meta-analysis to examine this potential association.
Methods. A systematic review of studies examining the association between any GBCA and NSF was performed. A search for controlled studies was conducted in MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials. If controlled data for a GBCA was not available, we searched for case reports and series. Relevant data were extracted and meta-analyses were performed.
Results. Seven of 144 identified studies met inclusion criteria; gadodiamide was the sole or predominant GBCA in four of these; one study exclusively examined gadopentetate. Other GBCAs were not specifically examined in controlled or uncontrolled studies. Meta-analysis of controlled trials demonstrated a significant association between GBCA exposure and NSF [odds ratio (OR) 26.7; 95% confidence interval (CI) 10.3–69.4] and gadodiamide and NSF (OR 20.0; 95% CI 3.7–107.8). Examination of the evidence using established criteria suggested that this association was causal.
Conclusions. The current state of evidence suggests an association and potentially causal link between the use of GBCAs and the development of NSF among patients with advanced kidney disease. Additional study is warranted to clarify the potential association of GBCAs other than gadodiamide with NSF.
Keywords: chronic kidney disease; gadolinium; meta-analysis; nephrogenic systemic fibrosis; systematic review
Received for publication: 25. 8.08
Accepted in revised form: 26. 9.08
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. L. Davis and J. L. Abraham Lanthanum deposition in a dialysis patient Nephrol. Dial. Transplant., October 1, 2009; 24(10): 3247 - 3250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Boehm Which laboratory parameters are characteristic for nephrogenic systemic fibrosis? Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2293 - 2293. [Full Text] [PDF]
|
|
|
|
|
|
R. Agarwal, S. M. Brunelli, and C. A. Umscheid Reply Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2293 - 2294. [Full Text] [PDF]
|
|
|
|
 |
|
 A Power, N Duncan, and C Goodlad Management of the dialysis patient for the hospital physician Postgrad. Med. J., July 1, 2009; 85(1005): 376 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kribben, O. Witzke, U. Hillen, J. Barkhausen, A. E. Daul, and R. Erbel Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. J. Am. Coll. Cardiol., May 5, 2009; 53(18): 1621 - 1628. [Abstract] [Full Text] [PDF]
|
|